CTC
AST

Central Trust Company’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Central Trust Company’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-41
Closed – – 1201
2018
Q4 		$0 Hold
41
– – ﹤0.01% 1307
2018
Q3 		$0 Hold
41
– – ﹤0.01% 1343
2018
Q2 		$0 Hold
41
– – ﹤0.01% 1392
2018
Q1 		$0 Hold
41
– – ﹤0.01% 1389
2017
Q4 		$0 Hold
41
– – ﹤0.01% 1439
2017
Q3 		$0 Hold
41
– – ﹤0.01% 1431
2017
Q2 		$0 Hold
41
– – ﹤0.01% 1374
2017
Q1 		$0 Hold
41
– – ﹤0.01% 1258
2016
Q4 		$0 Hold
41
– – ﹤0.01% 1242
2016
Q3 		$0 Hold
41
– – ﹤0.01% 1237
2016
Q2 		$0 Hold
41
– – ﹤0.01% 1208
2016
Q1 		$0 Buy
+41
New +$159 ﹤0.01% 1229
2015
Q4 		– Sell
-4
Closed – – 1264
2015
Q3 		$0 Hold
4
– – ﹤0.01% 1304
2015
Q2 		$0 Buy
+4
New +$38 ﹤0.01% 1273

Central Trust Company's AST Position: Q1 2019 in Review

Central Trust Company sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 41 shares.

Central Trust Company first reported a position in AST in Q2 2015 and held it in 14 quarters. The position peaked at $0 in Q4 2018. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.

  • Central Trust Company reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
  • Central Trust Company sold 41 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
  • Central Trust Company first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 14 quarters.
  • Central Trust Company's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q4 2018.
  • 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.

Based on Central Trust Company's 13F filing for Q1 2019, filed 26 Apr 2019.